Guam

The official policy architecture in Guam is administrative. DPHSS administers the controlled-substances system, operates registration, and manages a Controlled Substances Diversion Fund used for monitoring, equipment, contracts and staff training. That is a public-health-and-diversion model, not a psychedelic-innovation model.###

Recent official legislative activity that surfaced in the reviewed sources concerned updates to controlled-substance appendices for new synthetic drugs, not creation of psychedelic access rights. Public Law 36‑89 in 2022 updated the Guam Uniform Controlled Substances Act appendices.###

From a legal standpoint, Guam can support controlled-substances research through DPHSS registration, and the code expressly contemplates research as a registered activity. That is the correct lawful route if a local research programme were to exist.###

In the sources reviewed for this update, the visible public footprint is administrative and clinical rather than trial-centre based. Before publication, Blossom should manually recheck ClinicalTrials.gov and local institutional sources for any off-island-linked or military-affiliated activity serving Guam residents, because no strong territory-based psychedelic research hub was verified in the sources cited here.###

Implementation authority sits primarily with DPHSS. The agency administers registration, may inspect establishments, and manages monitoring and diversion infrastructure under the Controlled Substances Diversion Fund. Separate registration is required for each principal place of business or professional practice.###

That makes Guam operationally legible but not liberalised. Any future psychedelic development would most likely need to pass through DPHSS registration, possibly hospital or clinic partnerships, and any applicable federal approvals or DEA registrations. There is no verified territory-level facilitator, service-centre or public pilot-programme rulebook in the sources reviewed here.###

The most visible public-sector mental-health institution is the Guam Behavioral Health and Wellness Center, which provides mental-health and substance-use services. On the private side, Infusion Wellness markets ketamine IV services, and Blue Ocean Behavioral Health markets standard behavioural-health care with a broad local payer mix.###

That makes Guam’s ecosystem narrow and clinical rather than research- or policy-diverse. In the verified sources used here, the ecosystem is not anchored by a university-based psychedelic centre, a territory pilot programme, or a locally regulated healing-services sector.###

Over the next 12–24 months, Guam is unlikely to become a first-wave psychedelic-policy jurisdiction on the basis of the sources reviewed here. The more plausible short-term story is continued ordinary medical ketamine provision through private providers, plus any DPHSS-registered research activity that outside sponsors might build.###

For policy and investment audiences, Guam should be treated as an administratively straightforward but small and currently thin market. The main uncertainties are provider capacity, payer realities and whether any local institution chooses to use the existing registration pathway for controlled-substances research.###